CongenPharma

CongenPharma is a clinical-stage biotechnology company dedicated to developing novel therapies for rare pediatric endocrine disorders, with a primary focus on congenital hyperinsulinism (CHI). The company's lead program involves the use of glucagon-like peptide 1 (GLP-1) receptor antagonists to manage the life-threatening hypoglycemia associated with CHI. By targeting the underlying pathophysiology of insulin oversecretion, CongenPharma aims to provide non-surgical alternatives for patients who currently face limited treatment options. The company leverages deep clinical expertise from the Children's Hospital of Philadelphia to advance its pipeline of peptide and small molecule therapeutics.